Middle East And Africa Endoscopic Hemostasis Market
市场规模（十亿美元）
CAGR :
% 
USD
108.17 Million
USD
199.43 Million
2025
2033
 Forecast Period |
2026 –2033 |
 Market Size (Base Year) |
USD 108.17 Million |
 Market Size (Forecast Year) |
USD 199.43 Million |
 CAGR |
% |
| Major Markets Players |
|
Middle East and Africa Endoscopic Hemostasis Market, By Product Type (Mechanical Hemostasis Devices, Thermal Devices, Topical Agents and Injectables, and Others), Procedure (Upper Gastrointestinal Endoscopy, Lower Gastrointestinal Endoscopy, Bronchoscopic Hemostasis, and Others), Application (Gastrointestinal Bleeding, Non-Gastrointestinal Bleeding, Trauma Management, and Others), End User (Hospitals, Ambulatory Surgery Centers, Specialty Clinics, and Others), Distribution Channel (Direct Sales and Indirect Sales) - Industry Trends and Forecast to 2033
Middle East and Africa Endoscopic hemostasis market Size
- The Middle East and Africa endoscopic hemostasis market is expected to reach USD 199.43 million by 2033 from USD 108.17 million in 2025, growing with a substantial CAGR of 8.4% in the forecast period of 2026 to 2033
- The Middle East and Africa endoscopic hemostasis market is witnessing steady and robust growth, driven by the rising prevalence of gastrointestinal disorders, increasing incidence of colorectal cancer, peptic ulcers, and gastrointestinal bleeding, and the growing adoption of minimally invasive endoscopic procedures across the region..
- Market growth is further supported by stringent clinical guidelines, a strong focus on patient safety and procedural efficacy, and rising demand for advanced hemostatic technologies that improve procedural outcomes and reduce complication rates. Continuous advancements in endoscopic device design, including improved clips, coagulation systems, sprays, and combination therapies, are enhancing precision, ease of use, and clinical effectiveness..
Middle East and Africa Endoscopic Hemostasis Market Analysis
- Endoscopic Hemostasis products are becoming increasingly critical across the Middle East and Africa healthcare ecosystem, enabling clinicians to effectively manage gastrointestinal bleeding during diagnostic and therapeutic endoscopic procedures. These devices play a vital role in improving procedural safety, clinical outcomes, and patient recovery by ensuring rapid and reliable bleeding control. Endoscopic hemostasis solutions are widely used across key clinical settings, including hospitals, specialty clinics, and ambulatory surgical centers, for applications such as peptic ulcer bleeding, colorectal procedures, post-polypectomy bleeding, and tumor-related hemorrhage.
- Expanding healthcare infrastructure, rising volumes of endoscopic procedures, and increasing adoption of minimally invasive treatment approaches are fueling strong demand for endoscopic hemostasis devices in Middle East and Africa. Healthcare providers are increasingly incorporating advanced hemostatic technologies to improve procedural efficiency, reduce complication rates, shorten hospital stays, and enhance overall patient outcomes, thereby supporting sustained market growth.
- Additionally, stringent clinical guidelines, increasing emphasis on patient safety, and growing regulatory scrutiny are accelerating the adoption of advanced and clinically proven endoscopic hemostasis solutions. Medical device manufacturers are investing heavily in R&D to develop innovative products that offer improved precision, ease of use, and compatibility with modern endoscopic platforms, while meeting evolving regulatory standards and clinical performance requirements.
- Saudi Arabia is projected to lead the Middle East and Africa endoscopic hemostasis market in 2026, accounting for 22.40% of the regional market share. This leadership is supported by the country’s well-established healthcare infrastructure, high volume of endoscopic procedures, strong adoption of advanced medical technologies, and presence of leading medical device manufacturers. Favorable reimbursement frameworks, a skilled clinical workforce, and continuous investments in healthcare innovation further strengthen Saudi Arabia’s dominant position within the Middle East and African market.
- Israel is the fastest-growing country in the Middle East and Africa endoscopic hemostasis market, supported by early adoption of digital health and advanced endoscopy platforms, strong integration of AI-assisted diagnostics and image-guided endoscopic procedures, and a high level of clinical research participation in gastrointestinal and interventional endoscopy. The country’s well-structured referral pathways, emphasis on day-care and outpatient endoscopic treatments, and rapid commercial uptake of next-generation hemostatic devices by clinicians further accelerate procedural volumes. In addition, collaborations between hospitals, academic institutions, and medical device manufacturers, along with streamlined regulatory approval timelines for innovative technologies, continue to position as a leading early-adopter market, driving faster growth compared to other Middle East and African countries.
- The Mechanical Hemostasis Devices segment is dominating the Middle East and Africa endoscopic hemostasis market, accounting for 48.24% market share in 2025. This dominance is driven by the widespread clinical adoption of endoscopic clips and band ligation devices due to their proven efficacy, ease of deployment, cost-effectiveness, and suitability for a broad range of gastrointestinal bleeding indications. Their strong safety profile and compatibility with standard endoscopic procedures continue to support sustained demand across healthcare settings.
Report Scope and Middle East and Africa Endoscopic hemostasis market Segmentation
|
Attributes |
Middle East and Africa Endoscopic Hemostasis Market Insights |
|
Segments Covered |
|
|
Countries Covered |
Middle East and Africa
|
|
Key Market Players |
|
|
Market Opportunities |
|
|
Value Added Data Infosets |
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include Vendor Selection Criteria, Technological Advancement, Patent Analysis, regulatory framework, Innovation Tracker and strategic analysis Tariffs and Impact on the market. |
Middle East and Africa Endoscopic Hemostasis Market Trends
Increasing Adoption of Advanced Minimally Invasive Endoscopic Hemostasis Technologies
- The steady expansion of endoscopic and minimally invasive procedures across Middle East and Africa is a major factor driving the increased adoption of endoscopic hemostasis devices. As the incidence of gastrointestinal bleeding, colorectal disorders, and related conditions continues to rise, healthcare providers increasingly rely on advanced hemostasis solutions to ensure effective bleeding control, procedural safety, and improved patient outcomes across high-volume clinical environments.
- Endoscopic hemostasis devices play a critical role in ensuring clinical efficacy, patient safety, and procedural reliability throughout diagnostic and therapeutic endoscopy. By enabling rapid bleeding control, reducing complication risks, and supporting minimally invasive treatment approaches, these devices help optimize procedural workflows while improving recovery times and overall quality of care across healthcare facilities.
- The growing adoption of advanced endoscopic technologies, including high-definition imaging, therapeutic endoscopy, and combination hemostasis techniques, has increased demand for high-performance hemostatic solutions. Innovations in mechanical clips, thermal coagulation systems, injection therapies, and topical hemostatic agents are enhancing procedural precision, treatment success rates, and clinician confidence while supporting evolving clinical practices.
- Healthcare providers across the care continuum are increasingly adopting endoscopic hemostasis devices to meet rising regulatory, safety, and clinical performance standards. Stringent clinical guidelines, growing emphasis on patient safety and outcome-based care, and increasing demand for minimally invasive interventions are encouraging hospitals and clinics to integrate advanced hemostasis technologies that ensure consistency, compliance, and high-quality care delivery.
- Overall, the expanding scale of endoscopic procedures, clinical innovation, and healthcare infrastructure development positions endoscopic hemostasis devices as an essential component of modern gastrointestinal care. These solutions support procedural efficiency, patient safety, regulatory compliance, and sustainable growth across Middle East and Africa’s evolving endoscopy landscape, making this insight readily reusable across regions by adapting healthcare system dynamics and adoption patterns.
Middle East and Africa Endoscopic Hemostasis Market Dynamics
Driver
Rise in Gastrointestinal Bleeding Cases
- The rising incidence of gastrointestinal bleeding has been established as a foundational force propelling growth in the global endoscopic hemostasis market. As the prevalence of upper and lower gastrointestinal bleeding conditions increases worldwide, demand for minimally invasive, endoscopy-based therapeutic interventions has been intensified. Endoscopic hemostasis offers critical clinical advantages, including rapid bleeding control, reduced need for surgical intervention, lower transfusion requirements, and shorter hospital stays, thereby positioning it as a first-line treatment modality in acute and chronic gastrointestinal bleeding management. Consequently, the escalation in gastrointestinal bleeding cases—driven by aging populations, higher prevalence of liver disease, anticoagulant use, and delayed care access during systemic healthcare disruptions—has translated into higher procedural volumes and broader adoption of advanced endoscopic hemostasis devices across hospitals and endoscopy centers globally.
- For instances,
- In September 2021, Medscape reported that upper gastrointestinal bleeding occurred at an incidence of approximately 100 cases per 100,000 population annually and remained one of the most common causes of emergency hospital admissions, underscoring a persistently high disease burden requiring endoscopic intervention.
- In June2023, Gastroenterology Research journal reported that mortality related to upper gastrointestinal bleeding in the U.S. increased between 2012 and 2021, with steeper increases observed toward the later years, indicating worsening clinical outcomes and intensified treatment requirements.
- In June 2023, StatPearls Publishing stated that gastrointestinal bleeding continues to represent a frequent global medical emergency, with urgent endoscopic diagnosis and hemostatic treatment remaining critical to reducing mortality and morbidity.
- In January 2025, the Journal of Clinical Medicine reported that patients with advanced liver disease exhibited significantly higher incidence of massive gastrointestinal bleeding episodes, reinforcing the link between chronic disease prevalence and increased need for endoscopic hemostasis.
- In September 2025, PubMed Central highlighted that upper gastrointestinal bleeding remained a life-threatening complication among chronic liver disease populations, sustaining elevated demand for endoscopic therapeutic procedures.
- The global escalation in gastrointestinal bleeding incidence is being firmly established as a permanent structural growth engine for the endoscopic hemostasis market. The continuous rise in acute bleeding events, combined with expanding populations affected by chronic liver disease, antithrombotic medication use, and age-related gastrointestinal pathology, is creating a sustained and non-cyclical requirement for endoscopic bleeding control. As clinical guidelines increasingly prioritize endoscopic therapy as first-line management, reliance on hemostasis technologies for emergency intervention, recurrence prevention, and complication management is being structurally reinforced. Furthermore, improving survival rates are extending patient monitoring and repeat intervention cycles, thereby multiplying lifetime procedural demand. This dynamic is anchoring endoscopic hemostasis adoption closely to global epidemiological trends, positioning this driver as a long-term foundational pillar for market expansion across developed and emerging healthcare systems.
Restraint/Challenge
High Cost and Technical Complexity of Endoscopic Hemostasis Devices
- Despite growing clinical adoption, the Middle East & Africa Endoscopic hemostasis market continues to face structural restraint due to the high cost and technical complexity of advanced endoscopic hemostasis devices. These technologies often require significant upfront capital investment for equipment procurement, continuous expenditure on consumables, and specialized maintenance. In addition, effective use of hemostatic endoscopic devices demands advanced physician training, skilled support staff, and sophisticated hospital infrastructure, limiting adoption in cost-sensitive healthcare systems. Public hospitals in low- and middle-income countries, and even budget-constrained facilities in developed regions, frequently encounter barriers related to affordability, reimbursement gaps, and workforce readiness. As a result, uneven access and slower penetration of advanced endoscopic hemostasis technologies persist, constraining broader market expansion.
- For Instance,
- In November 2022, according to the high cost of gastrointestinal endoscopy procedures and equipment is a major restraint. For example, TNE costs Euro 125.90 per procedure, while oral endoscopy costs Euro 184.10 and MACE costs Euro 407.10. Additionally, equipment maintenance and reprocessing add to the cost, with flexible endoscopes costing around Euro 79,330, making procedures expensive overall.
- In June 2024, Science direct highlighted that the high cost of gastrointestinal endoscopy is exacerbated in low-income and middle-income countries (LICs and LMICs) due to the lack of local maintenance and repair facilities. Scopes requiring repairs must be shipped abroad, incurring significant costs and delays. Additionally, cheaper second-hand and Chinese-manufactured endoscopes often lack adequate service and maintenance support.
- In October 2025, BMJ Open Gastroenterology published a micro-costing study showing that in a UK National Health Service hospital, the total per-procedure cost of reusable gastrointestinal endoscopes was an estimated GBP107.34, with capital and maintenance costs as major cost drivers, highlighting economic barriers to wide adoption of endoscopic equipment in public health settings.
- In August 2024, a ScienceDirect narrative review reported that purchase, maintenance, and associated logistics costs of endoscopy equipment remain a major barrier to developing and sustaining endoscopy services in low- and middle-income countries, due to high device cost and lack of infrastructure.
- In February 2025, as per science direct the high cost of gastrointestinal endoscopy is evident in various studies, especially for screening and surveillance. For instance, while general population screenings may not be cost-effective in Western regions, targeted surveillance for high-risk groups, such as those with gastric intestinal metaplasia, can still be cost-effective, with ICERs ranging from USD 20,739.1 to 98,402.2 per QALY.
- The compiled evidence clearly indicates that the high cost and technical complexity associated with gastrointestinal endoscopy and endoscopic hemostasis devices represent a persistent restraint on market growth. Substantial capital investment for equipment procurement, elevated per-procedure costs, and ongoing expenses related to maintenance, reprocessing, and repair significantly increase the overall cost burden on healthcare systems. These challenges are further intensified in low- and middle-income regions where limited technical infrastructure and lack of local servicing capabilities delay adoption and restrict procedural capacity. Even in developed healthcare systems, cost-effectiveness considerations influence screening strategies and limit widespread implementation. Collectively, these economic and operational constraints slow penetration of advanced endoscopic hemostasis technologies, reinforcing affordability and technical complexity as structural barriers to broader market expansion
Middle East and Africa Endoscopic hemostasis market Scope
The Middle East & Africa Endoscopic hemostasis market is categorized into five key segments: product type, procedure, application, end user, and distribution channel.
- By product type
On the basis of product type, the Middle East & Africa endoscopic hemostasis market is segmented into mechanical hemostasis devices, thermal devices, topical agents and injectables, and others. In 2026, the mechanical hemostasis devices segment is projected to dominate the Middle East and Africa endoscopic hemostasis market with the largest market share of 48.26%, owing to its widespread clinical preference for achieving immediate, controlled, and durable bleeding cessation during endoscopic interventions. Mechanical solutions such as clips and banding devices are routinely favored for their ability to provide precise vessel closure without inducing thermal tissue damage, thereby lowering rebleeding rates and post-procedure complications. Their applicability across a broad spectrum of bleeding scenarios, including peptic ulcers, variceal hemorrhage, and post-polypectomy bleeding, has resulted in consistently high utilization in both emergency and elective endoscopic settings. The strong reliance on mechanical hemostasis as a first-line therapeutic approach underscores its substantial contribution to overall market revenues and reinforces its dominant position within the product type landscape throughout the forecast period.
The topical agents and injectables segment is the fastest-growing segment in the endoscopic hemostasis market, with a CAGR of 8.8%. Growth is driven by the increasing incidence of gastrointestinal bleeding, widespread adoption of minimally invasive endoscopic procedures, and strong clinical demand for rapid-acting, easy-to-administer hemostatic solutions. Continuous advancements in formulation effectiveness, safety, and procedural efficiency are expected to sustain segment growth during the forecast period.
- By procedure
On the basis of procedure, the market is segmented into upper gastrointestinal endoscopy, lower gastrointestinal endoscopy, bronchoscopic hemostasis, and others. In 2026, the upper gastrointestinal endoscopy segment is projected to dominate the Middle East and Africa endoscopic hemostasis market with a market share of 48.02%, due to its extensive clinical adoption as the frontline procedural approach for managing acute and recurrent gastrointestinal bleeding. Upper GI endoscopy is widely relied upon for the diagnosis and immediate therapeutic control of bleeding ulcers, variceal hemorrhage, and Dieulafoy lesions, where rapid hemostatic intervention is clinically critical. The high procedural frequency in emergency departments and tertiary-care hospitals, combined with strong guideline support for early endoscopic intervention, is expected to sustain its leading market position. Its continued dominance is reflected in its substantial market share and steady growth trajectory through 2033, indicating persistent demand across both developed and emerging healthcare systems.
The lower gastrointestinal endoscopy segment is the fastest-growing application segment in the endoscopic hemostasis market, registering a CAGR of 8.8%. This growth is supported by rising prevalence of lower gastrointestinal bleeding conditions, increasing volumes of diagnostic and therapeutic colonoscopy procedures, and improved detection of colorectal disorders. Ongoing technological advancements in endoscopic hemostasis devices and growing emphasis on early diagnosis are expected to further drive adoption during the forecast period.
- By application
On the basis of application, the market is segmented into gastrointestinal bleeding, non-gastrointestinal bleeding, trauma management, and others. In 2026, the gastrointestinal bleeding segment is projected to dominate the Middle East and Africa endoscopic hemostasis market with a market share of 73.78%, owing to the high global prevalence of peptic ulcers, esophageal varices, and colorectal malignancies requiring endoscopic bleeding control. Gastrointestinal bleeding remains the most common indication for endoscopic hemostasis procedures, driving consistent utilization of mechanical, thermal, and topical hemostatic solutions across hospital and ambulatory care settings. The critical need for rapid bleeding control to reduce morbidity, hospital length of stay, and mortality is expected to reinforce sustained demand within this application segment. Its large share of total market value highlights the central role of gastrointestinal indications in shaping overall market dynamics during the forecast period.
The trauma management segment is the fastest-growing segment in the endoscopic hemostasis market, with a CAGR of 9.0%. Growth is driven by the increasing occurrence of acute bleeding associated with traumatic injuries and a growing preference for minimally invasive techniques that enable rapid bleeding control. Improved clinical outcomes, reduced surgical intervention rates, and advancements in emergency endoscopic hemostasis technologies are expected to support continued expansion of this segment over the forecast period.
- By end user
On the basis of end user, the market is segmented into hospitals, ambulatory surgery centers, specialty clinics, and others. In 2026, the hospitals segment is projected to dominate the Middle East and Africa endoscopic hemostasis market with the largest market share of 56.43%, due to the concentration of advanced endoscopy infrastructure, skilled gastroenterologists, and emergency care capabilities within hospital settings. Complex bleeding cases, including severe upper and lower gastrointestinal hemorrhage, are predominantly managed in public and private hospitals where comprehensive diagnostic and interventional resources are available. Higher patient inflow, greater procedural volumes, and established procurement frameworks further strengthen hospital demand for endoscopic hemostasis devices and consumables. This structural dependence on hospital-based care is expected to maintain the segment’s leading position through 2033 despite gradual growth in outpatient settings.
The ambulatory surgery centers segment is the fastest-growing end-user segment in the endoscopic hemostasis market, recording a CAGR of 8.8%. Growth is driven by the increasing shift toward outpatient endoscopic procedures, demand for cost-effective healthcare delivery, and shorter patient recovery times. Advancements in compact, efficient hemostasis devices suitable for outpatient settings are expected to further accelerate adoption during the forecast period.
- By distribution channel
On the basis of distribution channel, the market is segmented into direct sales and indirect sales, with indirect sales further segmented into online and offline channels. In 2026, the indirect sales segment is projected to dominate the Middle East and Africa endoscopic hemostasis market with the largest market share of 61.76% as procurement is largely conducted through distributors, group purchasing organizations, and regional medical supply networks. Indirect channels are widely preferred due to their ability to offer bundled products, inventory management support, and broader geographic reach, particularly in emerging markets and decentralized healthcare systems. Hospitals and ambulatory centers frequently rely on distributor-led sourcing to ensure consistent availability of critical hemostasis devices while optimizing procurement costs. This distribution structure is expected to continue driving higher adoption of indirect sales channels throughout the forecast period.
The indirect sales segment is the fastest-growing distribution channel in the endoscopic hemostasis market, with a CAGR of 8.5%. This growth is supported by the expanding role of distribution partners and group purchasing networks in enhancing product accessibility and supply efficiency. Increasing reliance on centralized procurement models, bundled purchasing agreements, and regional distributor expertise is expected to continue driving growth of the indirect sales channel throughout the forecast period.
Middle East and Africa Endoscopic Hemostasis Market Regional Analysis
- Saudi Arabia represents one of the most important markets for endoscopic hemostasis devices, supported by its advanced healthcare infrastructure, strong medical device manufacturing base, and high adoption of minimally invasive endoscopic procedures. Continuous clinical innovation in gastroenterology, a high volume of diagnostic and therapeutic endoscopies, and strict clinical and regulatory standards are driving steady adoption of advanced mechanical, thermal, and topical hemostasis solutions across hospitals and specialty care centers.
- The Israel is witnessing growing demand for endoscopic hemostasis technologies as increasing prevalence of gastrointestinal disorders, an aging population, and rising emphasis on minimally invasive treatment approaches reshape clinical practice. Healthcare providers are increasingly focused on improving patient safety, reducing procedure-related complications, and enhancing clinical efficiency, which is accelerating the adoption of reliable and cost-effective hemostasis devices across public and private healthcare settings.
- South Africa continues to emerge as a key growth hub for the endoscopic hemostasis market, driven by strong clinical expertise in gastroenterology, expanding access to advanced endoscopic services, and increasing focus on patient-centered and outcome-driven care. The country’s emphasis on clinical quality, safety, and technological innovation is encouraging healthcare institutions to adopt advanced hemostasis solutions that improve procedural outcomes, support minimally invasive interventions, and comply with evolving regulatory and healthcare standards.
Saudi Arabia Endoscopic Hemostasis Market Insight
The Saudi Arabia endoscopic hemostasis market is gaining strong traction due to the country’s high volume of gastrointestinal endoscopic procedures and early adoption of advanced therapeutic endoscopy techniques. Saudi Arabian hospitals and specialty clinics place strong emphasis on clinical precision, procedural reliability, and evidence-based device selection, driving consistent demand for high-performance mechanical and energy-based hemostasis solutions. In addition, the presence of leading medical device manufacturers, well-established clinical training programs, and strict regulatory and quality standards is fostering rapid uptake of technologically advanced hemostasis devices. Saudi Arabia’s focus on procedural standardization, patient safety, and outcome optimization reinforces its position as a technology-led and innovation-driven market within Middle East and Africa.
South Africa Endoscopic Hemostasis Market Insight
The South Africa Endoscopic Hemostasis Market continues to expand as healthcare providers prioritize minimally invasive treatment pathways, efficiency in endoscopy units, and reduction of procedure-related complications. Rising incidence of gastrointestinal bleeding conditions, combined with increasing demand on NHS endoscopy services, is accelerating adoption of cost-effective, easy-to-use hemostasis devices that support high procedural throughput. Strong emphasis on clinical guidelines, value-based care, and standardized treatment protocols is shaping purchasing decisions, while growing use of ambulatory and day-care endoscopy settings is further supporting demand. These factors collectively position the South Africa market as one driven by access, efficiency, and scalable clinical adoption rather than device manufacturing concentration.
Middle East and Africa Endoscopic Hemostasis Market Share
The Specialty Food Ingredients industry is primarily led by well-established companies, including:
- Micro-Tech Endoscopy (China)
- Taewoong Medical Co., Ltd. (South Korea)
- Ovesco Endoscopy AG (Saudi Arabia)
- Apollo Endosurgery, Inc. (U.S.)
- Argon Medical Devices, Inc. (U.S.)
- Olympus Corporation (Japan)
- Boston Scientific Corporation (U.S.)
- CONMED Corporation (U.S.)
- Medtronic (Ireland)
- Cook (U.S.)
- ERBE Elektromedizin GmbH (Saudi Arabia)
- Karl Storz SE & Co. KG (Saudi Arabia)
- Pentax Medical (Japan)
- Endoskopie Technik Gerhard (Saudi Arabia)
- Merit Medical Systems, Inc. (U.S.)
- Diversatek, Inc. (U.S.)
- STERIS plc (U.K.)
- B. Braun SE (Saudi Arabia)
- Duomed Group (Belgium)
Latest Developments in the Middle East and Africa Endoscopic Hemostasis Market
- In December 2025, Olympus tripled its corporate venture capital fund commitment by launching Olympus Innovation Ventures Fund II with an additional $150 million to invest in MedTech startups focused on endoscopy, diagnostics, digital health, and related innovation fields to reinforce long-term growth and technological leadership.
- In October 2025, Boston Scientific announced an agreement to acquire Nalu Medical, Inc., a privately held medical device company focused on implantable neurostimulation technologies for chronic pain. The acquisition was positioned to strengthen Boston Scientific’s neuromodulation portfolio, accelerate innovation in pain management, and expand treatment options for patients with chronic pain conditions.
- In October 2025, CONMED Corporation announced a strategic exit from its gastroenterology business, divesting its GI product lines and related assets as part of a portfolio realignment to concentrate on core surgical and orthopaedic solutions. The move was positioned to streamline the company’s product focus, sharpen investment in high-growth procedural areas, and improve long-term revenue and margin profiles by reallocating resources toward CONMED’s flagship device platforms and emerging technologies.
- In August 2025, the U.S. Food and Drug Administration (FDA) approved the first-of-its-kind IDE clinical study of Cook Medical’s ADVANCE EVERO 18 everolimus-coated PTA balloon catheter, enabling evaluation of its safety and effectiveness in treating symptomatic peripheral arterial disease. The decision marked a milestone for drug-coated balloon technology, supporting Cook’s advancement of next-generation endovascular therapies aimed at reducing restenosis and improving long-term vessel patency in patients with lower-extremity arterial disease..
- In July, ESGE guidelines on topical hemostatic agents reported Ankaferd Blood Stopper with 73%-100% hemostasis rates for GI bleeding sources like peptic ulcers and malignancies in endoscopic use.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END-USER COVERAGE GRID
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTERS FIVE FORCES ANALYSIS
4.2 BRAND OUTLOOK
4.2.1 BRAND COMPARATIVE ANALYSIS OF KEY MIDDLE EAST AND AFRICA PLAYERS
4.2.1.1 BRAND COMPARATIVE NARRATIVE (ANALYTICAL OVERVIEW)
4.2.2 PRODUCT VS BRAND OVERVIEW — MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET
4.2.2.1 PRODUCT OVERVIEW — ENDOSCOPIC HEMOSTASIS DEVICES
4.2.2.2 BRAND OVERVIEW — INFLUENCE ON MIDDLE EAST AND AFRICA CLINICAL ADOPTION
4.3 CONSUMER BUYING BEHAVIOUR
4.3.1 CLINICAL EFFECTIVENESS AND PATIENT OUTCOMES
4.3.2 COST AND VALUE CONSIDERATIONS
4.3.3 COMPATIBILITY AND INTEGRATION
4.3.4 TRAINING REQUIREMENTS AND EASE OF USE
4.3.5 REIMBURSEMENT AND HEALTHCARE POLICY ALIGNMENT
4.3.6 PROCUREMENT PROCESSES AND BULK AGREEMENTS
4.3.7 INFLUENCE OF CLINICAL STAKEHOLDERS
4.3.8 TRENDS IN BUYER BEHAVIOUR
4.3.9 CONCLUSION
4.4 PATENT ANALYSIS
4.4.1 PATENT QUALITY AND STRENGTH – MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET
4.4.2 COUNTRY PATENT LANDSCAPE
4.4.3 IP STRATEGY AND MANAGEMENT
4.4.4 LICENSING AND COLLABORATION
4.5 RAW MATERIAL COVERAGE
4.5.1 METALLIC COMPONENTS AND ALLOY SYSTEMS
4.5.2 POLYMERIC AND SYNTHETIC MATERIALS
4.5.3 NATURAL AND BIOCOMPATIBLE MATERIALS
4.5.4 ELECTRICAL AND THERMAL MATERIAL SYSTEMS
4.5.5 EXPENDABLE ACCESSORIES AND SINGLE-USE MATERIALS
4.6 TECHNOLOGICAL ADVANCEMENTS IN MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET
4.6.1 ENHANCED MECHANICAL HEMOSTASIS TOOLS
4.6.2 ADVANCED THERMAL COAGULATION AND ENERGY-BASED SYSTEMS
4.6.3 NOVEL TOPICAL HEMOSTATIC AGENTS
4.6.4 INTEGRATION WITH ADJUNCTIVE DIAGNOSTIC TECHNOLOGIES
4.6.5 DEVELOPMENT OF MULTIFUNCTIONAL AND COMBINATION DEVICES
4.6.6 IMPROVED USER ERGONOMICS AND DEVICE DEPLOYMENT SYSTEMS
4.6.7 CONCLUSION
4.7 VALUE CHAIN ANALYSIS
4.7.1 OVERVIEW
4.7.2 RAW MATERIALS & COMPONENTS
4.7.3 DEVICE DESIGN, R&D & MANUFACTURING
4.7.4 PROCESSING, FINISHING & STERILIZATION
4.7.5 PACKAGING & LABELING
4.7.6 LOGISTICS, DISTRIBUTION & COMMERCIALIZATION
4.7.7 CONCLUSION
4.8 VENDOR SELECTION CRITERIA
4.8.1 CLINICAL PERFORMANCE
4.8.2 REGULATORY COMPLIANCE AND APPROVALS
4.8.3 COST AND TOTAL VALUE PROPOSITION
4.8.4 SUPPLY CHAIN ROBUSTNESS AND LOGISTICS
4.8.5 SUPPORT, TRAINING AND CLINICAL EDUCATION
4.8.6 QUALITY SYSTEMS AND REPROCESSING GUIDANCE
4.8.7 REPUTATION, PEER ACCEPTANCE AND POST-MARKET PERFORMANCE
4.8.8 INNOVATION AND FUTURE-READINESS
4.9 COMPANY EVALUATION QUADRANT
4.1 PROFIT MARGIN SCENARIO
4.10.1 MARGIN IMPROVEMENT DRIVERS
4.10.2 COST PRESSURE
4.10.3 REGIONAL VARIATIONS
4.10.4 FUTURE SCENARIOS
4.11 CLIMATE CHANGE SCENARIO
4.11.1 ENVIRONMENTAL CONCERNS
4.11.2 INDUSTRY RESPONSE
4.11.3 GOVERNMENT’S ROLE
4.11.4 ANALYST RECOMMENDATIONS
4.12 INNOVATION TRACKER AND STRATEGIC ANALYSIS
4.12.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
4.12.1.1 JOINT VENTURES
4.12.1.2 MERGERS AND ACQUISITIONS
4.12.1.3 LICENSING AND PARTNERSHIP
4.12.1.4 TECHNOLOGY COLLABORATIONS
4.12.2 STRATEGIC DIVESTMENTS
4.12.3 STAGE OF DEVELOPMENT
4.12.4 TIMELINES AND MILESTONES
4.12.5 INNOVATION STRATEGIES AND METHODOLOGIES
4.12.6 RISK ASSESSMENT AND MITIGATION
4.12.7 FUTURE OUTLOOK
4.13 PRICING ANALYSIS
4.13.1 HEMOSTATIC CLIPS AND FORCEPS PRICING
4.13.2 BANDING AND COAGULATION DEVICES
4.13.3 REGULATORY AND REIMBURSEMENT IMPACT
4.14 SUPPLY CHAIN ANALYSIS
4.14.1 OVERVIEW
4.14.2 LOGISTIC COST SCENARIO
4.14.3 IMPORTANCE OF LOGISTICS SERVICE PROVIDERS
4.14.4 CONCLUSION
5 TARIFFS & IMPACT ON THE MARKET
5.1 OVERVIEW
5.2 CURRENT TARIFF RATE (S) IN TOP-5 COUNTRY MARKETS
5.3 OUTLOOK: LOCAL PRODUCTION V/S IMPORT RELIANCE
5.4 VENDOR SELECTION CRITERIA
5.5 IMPACT ON SUPPLY CHAIN
5.5.1 RAW MATERIAL PROCUREMENT
5.5.2 MANUFACTURING AND PRODUCTION
5.5.3 LOGISTICS AND DISTRIBUTION
5.5.4 PRICE PITCHING AND POSITION OF MARKET
5.6 INDUSTRY PARTICIPANTS: PROACTIVE MOVES
5.6.1 SUPPLY CHAIN OPTIMIZATION
5.6.2 JOINT VENTURE ESTABLISHMENTS
5.7 IMPACT ON PRICES
5.8 REGULATORY INCLINATION
5.8.1 GEOPOLITICAL SITUATION
5.8.2 TRADE PARTNERSHIPS BETWEEN THE COUNTRIES
5.8.2.1 FREE TRADE AGREEMENTS
5.8.2.2 ALLIANCES ESTABLISHMENTS
5.8.3 STATUS ACCREDITATION (INCLUDING MFTN)
5.8.4 DOMESTIC COURSE OF CORRECTION
5.8.4.1 INCENTIVE SCHEMES TO BOOST PRODUCTION OUTPUTS
5.8.4.2 ESTABLISHMENT OF SEZS/INDUSTRIAL PARKS
6 REGULATION COVERAGE
6.1 PRODUCT CODES
6.2 CERTIFIED STANDARDS
6.3 SAFETY STANDARDS
6.3.1 MATERIAL HANDLING & STORAGE
6.3.2 TRANSPORT & PRECAUTIONS
6.3.3 HAZARD IDENTIFICATION
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISE IN GASTROINTESTINAL BLEEDING CASES
7.1.2 AGING POPULATION DRIVING INCREASED DEMAND FOR GI DISORDERS
7.1.3 ADOPTION OF MINIMALLY INVASIVE ENDOSCOPIC PROCEDURES
7.1.4 RISING AWARENESS AND EXPANDED SCREENING PROGRAMS FOR GASTROINTESTINAL ENDOSCOPY
7.2 RESTRAINTS
7.2.1 HIGH COST AND TECHNICAL COMPLEXITY OF ENDOSCOPIC HEMOSTASIS DEVICES
7.2.2 LIMITED AWARENESS IN LOW-INCOME COUNTRIES
7.3 OPPORTUNITIES
7.3.1 TECHNOLOGICAL ADVANCEMENTS IN HEMOSTASIS DEVICES
7.3.2 EXPANSION IN EMERGING MARKETS (ASIA-PACIFIC, LATIN AMERICA)
7.3.3 GROWING ADOPTION OF HOME-BASED AND CAPSULE ENDOSCOPY SOLUTIONS
7.4 CHALLENGES
7.4.1 REIMBURSEMENT ISSUES FOR ENDOSCOPIC PROCEDURES
7.4.2 COMPLEXITIES IN ENDOSCOPE REPROCESSING AND STERILIZATION PROCESSES
8 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE
8.1 OVERVIEW
8.2 MECHANICAL HEMOSTASIS DEVICES
8.2.1 MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE
8.2.1.1 HEMOSTATIC CLIPS
8.2.1.1.1 HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE
8.2.1.1.1.1 THROUGH-THE-SCOPE (TTS) CLIPS
8.2.1.1.1.2 OVER-THE-SCOPE (OTS) CLIPS
8.2.1.1.2 HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL
8.2.1.1.2.1 STAINLESS STEEL
8.2.1.1.2.2 TITANIUM
8.2.1.2 BANDING DEVICES
8.2.1.2.1 BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE
8.2.1.2.1.1 VARICEAL BANDING KITS
8.2.1.2.1.2 OESOPHAGEAL BANDING DEVICES
8.2.1.3 HEMOSTATIC FORCEPS
8.2.1.4 OTHERS
8.2.2 MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION
8.2.2.1 NORTH AMERICA
8.2.2.2 EUROPE
8.2.2.3 ASIA-PACIFIC
8.2.2.4 SOUTH AMERICA
8.2.2.5 MIDDLE EAST & AFRICA
8.3 THERMAL DEVICES
8.3.1 THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE
8.3.1.1 ARGON PLASMA COAGULATORS
8.3.1.2 HEATER PROBES
8.3.1.3 BIPOLAR COAGULATION DEVICES
8.3.1.3.1 BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE
8.3.1.3.1.1 MONOPOLAR
8.3.1.3.1.2 BIPOLAR
8.3.1.3.2 BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION
8.3.1.3.2.1 UPPER GI BLEEDING
8.3.1.3.2.2 LOWER GI BLEEDING
8.3.1.4 OTHERS
8.3.2 THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION
8.3.2.1 NORTH AMERICA
8.3.2.2 EUROPE
8.3.2.3 ASIA-PACIFIC
8.3.2.4 SOUTH AMERICA
8.3.2.5 MIDDLE EAST & AFRICA
8.4 TOPICAL AGENTS AND INJECTABLES
8.4.1 TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE
8.4.1.1 EPINEPHRINE INJECTION
8.4.1.2 HEMOSTATIC SPRAY (POWDER)
8.4.1.3 HEMOSTATIC GELS
8.4.1.4 FIBRIN SEALANTS
8.4.1.5 SCLEROSING AGENTS
8.4.2 TOPICAL AGENTS AND INJECTABLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION
8.4.2.1 NORTH AMERICA
8.4.2.2 EUROPE
8.4.2.3 ASIA-PACIFIC
8.4.2.4 SOUTH AMERICA
8.4.2.5 MIDDLE EAST & AFRICA
8.5 OTHERS
8.5.1 OTHERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION
8.5.1.1 NORTH AMERICA
8.5.1.2 EUROPE
8.5.1.3 ASIA-PACIFIC
8.5.1.4 SOUTH AMERICA
8.5.1.5 MIDDLE EAST & AFRICA
9 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE TYPE
9.1 OVERVIEW
9.2 UPPER GASTROINTESTINAL ENDOSCOPY
9.2.1 UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE
9.2.1.1 BLEEDING ULCER MANAGEMENT
9.2.1.2 VARICEAL BLEEDING
9.2.1.3 DIEULAFOY LESION
9.2.2 UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION
9.2.2.1 NORTH AMERICA
9.2.2.2 EUROPE
9.2.2.3 ASIA-PACIFIC
9.2.2.4 SOUTH AMERICA
9.2.2.5 MIDDLE EAST & AFRICA
9.3 LOWER GASTROINTESTINAL ENDOSCOPY
9.3.1 LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE
9.3.1.1 COLONIC BLEEDING
9.3.1.2 DIVERTICULAR BLEEDING
9.3.2 LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION
9.3.2.1 NORTH AMERICA
9.3.2.2 EUROPE
9.3.2.3 ASIA-PACIFIC
9.3.2.4 SOUTH AMERICA
9.3.2.5 MIDDLE EAST & AFRICA
9.4 BRONCHOSCOPIC HEMOSTASIS
9.4.1 BRONCHOSCOPIC HEMOSTASIS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION
9.4.1.1 NORTH AMERICA
9.4.1.2 EUROPE
9.4.1.3 ASIA-PACIFIC
9.4.1.4 SOUTH AMERICA
9.4.1.5 MIDDLE EAST & AFRICA
9.5 OTHERS
9.5.1 OTHERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION
9.5.1.1 NORTH AMERICA
9.5.1.2 EUROPE
9.5.1.3 ASIA-PACIFIC
9.5.1.4 SOUTH AMERICA
9.5.1.5 MIDDLE EAST & AFRICA
10 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION
10.1 OVERVIEW
10.2 GASTROINTESTINAL BLEEDING
10.2.1 GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE
10.2.1.1 PEPTIC ULCER BLEEDING
10.2.1.2 ESOPHAGEAL VARICES
10.2.1.3 COLORECTAL CANCERS
10.2.2 GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE
10.2.2.1 MECHANICAL HEMOSTASIS DEVICES
10.2.2.2 THERMAL DEVICES
10.2.2.3 TOPICAL AGENTS AND INJECTABLES
10.2.2.4 OTHERS
10.2.3 GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION
10.2.3.1 NORTH AMERICA
10.2.3.2 EUROPE
10.2.3.3 ASIA-PACIFIC
10.2.3.4 SOUTH AMERICA
10.2.3.5 MIDDLE EAST & AFRICA
10.3 NON-GASTROINTESTINAL BLEEDING
10.3.1 NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE
10.3.1.1 NASAL BLEEDING (EPISTAXIS)
10.3.1.2 POST-SURGICAL BLEEDING
10.3.2 NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE
10.3.2.1 MECHANICAL HEMOSTASIS DEVICES
10.3.2.2 THERMAL DEVICES
10.3.2.3 TOPICAL AGENTS & INJECTABLES
10.3.2.4 OTHERS
10.3.3 NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)
10.3.3.1 NORTH AMERICA
10.3.3.2 EUROPE
10.3.3.3 ASIA-PACIFIC
10.3.3.4 SOUTH AMERICA
10.3.3.5 MIDDLE EAST & AFRICA
10.4 TRAUMA MANAGEMENT
10.4.1 TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE
10.4.1.1 MECHANICAL HEMOSTASIS DEVICES
10.4.1.2 THERMAL DEVICES
10.4.1.3 TOPICAL AGENTS & INJECTABLES
10.4.1.4 OTHERS
10.4.2 TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION
10.4.2.1 NORTH AMERICA
10.4.2.2 EUROPE
10.4.2.3 ASIA-PACIFIC
10.4.2.4 SOUTH AMERICA
10.4.2.5 MIDDLE EAST & AFRICA
10.5 OTHERS
10.5.1 OTHERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION
10.5.1.1 NORTH AMERICA
10.5.1.2 EUROPE
10.5.1.3 ASIA-PACIFIC
10.5.1.4 SOUTH AMERICA
10.5.1.5 MIDDLE EAST & AFRICA
11 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.2.1 HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE
11.2.1.1 PUBLIC
11.2.1.2 PRIVATE
11.2.2 HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION
11.2.2.1 NORTH AMERICA
11.2.2.2 EUROPE
11.2.2.3 ASIA-PACIFIC
11.2.2.4 SOUTH AMERICA
11.2.2.5 MIDDLE EAST & AFRICA
11.3 AMBULATORY SURGERY CENTERS
11.3.1 AMBULATORY SURGERY CENTERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION
11.3.1.1 NORTH AMERICA
11.3.1.2 EUROPE
11.3.1.3 ASIA-PACIFIC
11.3.1.4 SOUTH AMERICA
11.3.1.5 MIDDLE EAST & AFRICA
11.4 SPECIALTY CLINICS
11.4.1 SPECIALTY CLINICS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION
11.4.1.1 NORTH AMERICA
11.4.1.2 EUROPE
11.4.1.3 ASIA-PACIFIC
11.4.1.4 SOUTH AMERICA
11.4.1.5 MIDDLE EAST & AFRICA
11.5 OTHERS
11.5.1 OTHERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION
11.5.1.1 NORTH AMERICA
11.5.1.2 EUROPE
11.5.1.3 ASIA-PACIFIC
11.5.1.4 SOUTH AMERICA
11.5.1.5 MIDDLE EAST & AFRICA
12 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 INDIRECT SALES
12.2.1 INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE
12.2.1.1 OFFLINE
12.2.1.2 ONLINE
12.2.2 INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION
12.2.2.1 NORTH AMERICA
12.2.2.2 EUROPE
12.2.2.3 ASIA-PACIFIC
12.2.2.4 SOUTH AMERICA
12.2.2.5 MIDDLE EAST & AFRICA
12.3 DIRECT SALES
12.3.1 DIRECT SALES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION
12.3.1.1 NORTH AMERICA
12.3.1.2 EUROPE
12.3.1.3 ASIA-PACIFIC
12.3.1.4 SOUTH AMERICA
12.3.1.5 MIDDLE EAST & AFRICA
13 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET, BY REGION
13.1 MIDDLE EAST AND AFRICA
13.1.1 SAUDI ARABIA
13.1.2 UNITED ARAB EMIRATES
13.1.3 EGYPT
13.1.4 ISRAEL
13.1.5 QATAR
13.1.6 KUWAIT
13.1.7 OMAN
13.1.8 BAHRAIN
13.1.9 REST OF MIDDLE EAST AND AFRICA
14 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: GLOBAL
15 SWOT ANALYSIS
16 COMPANY PROFILES MANUFACTURERS
16.1 OLYMPUS CORPORATION
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENT
16.2 BOSTON SCIENTIFIC CORPORATION
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENT
16.3 CONMED CORPORATION
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENT
16.4 MEDTRONIC
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENT
16.5 COOK
16.5.1 COMPANY SNAPSHOT
16.5.2 COMPANY SHARE ANALYSIS
16.5.3 PRODUCT PORTFOLIO
16.5.4 RECENT DEVELOPMENT
16.6 ANKAFERD
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVEOPMENT
16.7 B. BRAUN SE
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVEOPMENT
16.8 CREO MEDICAL GMBH
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENT
16.9 DIVERSATEK, INC.
16.9.1 COMPANY SNAPSHOT
16.9.2 PRODUCT PORTFOLIO
16.9.3 RECENT DEVEOPMENT
16.1 DUOMED GROUP
16.10.1 COMPANY SNAPSHOT
16.10.2 PRODUCT PORTFOLIO
16.10.3 RECENT DEVEOPMENT
16.11 ENDOCLOT PLUS, INC.
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVEOPMENT
16.12 ERBE ELEKTROMEDIZIN GMBH
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT DEVELOPMENT
16.13 FUJIFILM HOLDINGS CORPORATION
16.13.1 COMPANY SNAPSHOT
16.13.2 REVENUE ANALYSIS
16.13.3 PRODUCT PORTFOLIO
16.13.4 RECENT DEVELOPMENT
16.14 JOHNSON & JOHNSON (ETHICON)
16.14.1 COMPANY SNAPSHOT
16.14.2 REVENUE ANALYSIS
16.14.3 PRODUCT PORTFOLIO
16.14.4 RECENT DEVEOPMENT
16.15 KARL STORZ SE & CO. KG, TUTTLINGEN
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVEOPMENT
16.16 MEDITALIA S.R.L.
16.16.1 COMPANY SNAPSHOT
16.16.2 PRODUCT PORTFOLIO
16.16.3 RECENT DEVELOPMENT
16.17 MICRO-TECH ENDOSCOPY
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENT
16.18 MTW ENDOSKOPIE MANUFAKTU
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVEOPMENT
16.19 OVESCO ENDOSCOPY AG
16.19.1 COMPANY SNAPSHOT
16.19.2 PRODUCT PORTFOLIO
16.19.3 RECENT DEVEOPMENT
16.2 PENTAX MEDICAL
16.20.1 COMPANY SNAPSHOT
16.20.2 SOLUTION PORTFOLIO
16.20.3 RECENT DEVELOPMENT
16.21 STERIS
16.21.1 COMPANY SNAPSHOT
16.21.2 REVENUE ANALYSIS
16.21.3 PRODUCT PORTFOLIO
16.21.4 RECENT DEVELOPMENT
17 COMPANY PROFILES DISTRIBUTOR
17.1 BOSTON IVY HEALTHCARE SOLUTIONS PRIVATE LIMITED
17.1.1 COMPANY SNAPSHOT
17.1.2 PRODUCT PORTFOLIO
17.1.3 RECENT DEVELOPMENT
17.2 CARDINAL HEALTH
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 PRODUCT PORTFOLIO
17.2.4 RECENT DEVEOPMENT
17.3 HENRY SCHEIN, INC.
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 PRODUCT PORTFOLIO
17.3.4 RECENT DEVEOPMENT
17.4 MCKESSON MEDICAL-SURGICAL INC.
17.4.1 COMPANY SNAPSHOT
17.4.2 PRODUCT PORTFOLIO
17.4.3 RECENT DEVEOPMENT
17.5 MFI MEDICAL
17.5.1 COMPANY SNAPSHOT
17.5.2 PRODUCT PORTFOLIO
17.5.3 RECENT DEVEOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
表格列表
TABLE 1 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 2 MIDDLE EAST AND AFRICA MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 3 MIDDLE EAST AND AFRICA HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 4 MIDDLE EAST AND AFRICA HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)
TABLE 5 MIDDLE EAST AND AFRICA BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 6 MIDDLE EAST AND AFRICA MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 7 MIDDLE EAST AND AFRICA THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 8 MIDDLE EAST AND AFRICA BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)
TABLE 9 MIDDLE EAST AND AFRICA BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 10 MIDDLE EAST AND AFRICA THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 11 MIDDLE EAST AND AFRICA TOPICAL AGENTS & INJECTABLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 12 MIDDLE EAST AND AFRICA TOPICAL AGENTS AND INJECTABLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 13 MIDDLE EAST AND AFRICA OTHERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 14 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)
TABLE 15 MIDDLE EAST AND AFRICA UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 16 MIDDLE EAST AND AFRICA UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 17 MIDDLE EAST AND AFRICA LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 18 MIDDLE EAST AND AFRICA LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 19 MIDDLE EAST AND AFRICA BRONCHOSCOPIC HEMOSTASIS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 20 MIDDLE EAST AND AFRICA OTHERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 21 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 22 MIDDLE EAST AND AFRICA GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 23 MIDDLE EAST AND AFRICA GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 24 MIDDLE EAST AND AFRICA GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 25 MIDDLE EAST AND AFRICA NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 26 MIDDLE EAST AND AFRICA NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 27 MIDDLE EAST AND AFRICA NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 28 MIDDLE EAST AND AFRICA TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 29 MIDDLE EAST AND AFRICA TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 30 MIDDLE EAST AND AFRICA OTHERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 31 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 32 MIDDLE EAST AND AFRICA HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 33 MIDDLE EAST AND AFRICA HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 34 MIDDLE EAST AND AFRICA AMBULATORY SURGERY CENTERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 35 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 36 MIDDLE EAST AND AFRICA OTHERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 37 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 38 MIDDLE EAST AND AFRICA INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 39 MIDDLE EAST AND AFRICA INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 40 MIDDLE EAST AND AFRICA DIRECT SALES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 41 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET, BY COUNTRY, 2018-2033 (USD THOUSAND)
TABLE 42 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 43 MIDDLE EAST AND AFRICA MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 44 MIDDLE EAST AND AFRICA HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 45 MIDDLE EAST AND AFRICA HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)
TABLE 46 MIDDLE EAST AND AFRICA BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 47 MIDDLE EAST AND AFRICA THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 48 MIDDLE EAST AND AFRICA BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)
TABLE 49 MIDDLE EAST AND AFRICA BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 50 MIDDLE EAST AND AFRICA TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 51 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)
TABLE 52 MIDDLE EAST AND AFRICA UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 53 MIDDLE EAST AND AFRICA LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 54 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 55 MIDDLE EAST AND AFRICA GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 56 MIDDLE EAST AND AFRICA GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 57 MIDDLE EAST AND AFRICA NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 58 MIDDLE EAST AND AFRICA NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 59 MIDDLE EAST AND AFRICA TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 60 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 61 MIDDLE EAST AND AFRICA HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 62 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 63 MIDDLE EAST AND AFRICA INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 64 SAUDI ARABIA ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 65 SAUDI ARABIA MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 66 SAUDI ARABIA HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 67 SAUDI ARABIA HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)
TABLE 68 SAUDI ARABIA BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 69 SAUDI ARABIA THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 70 SAUDI ARABIA BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)
TABLE 71 SAUDI ARABIA BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 72 SAUDI ARABIA TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 73 SAUDI ARABIA ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)
TABLE 74 SAUDI ARABIA UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 75 SAUDI ARABIA LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 76 SAUDI ARABIA ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 77 SAUDI ARABIA GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 78 SAUDI ARABIA GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 79 SAUDI ARABIA NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 80 SAUDI ARABIA NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 81 SAUDI ARABIA TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 82 SAUDI ARABIA ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 83 SAUDI ARABIA HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 84 SAUDI ARABIA ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 85 SAUDI ARABIA INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 86 SOUTH AFRICA
TABLE 87 SOUTH AFRICA ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 88 SOUTH AFRICA MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 89 SOUTH AFRICA HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 90 SOUTH AFRICA HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)
TABLE 91 SOUTH AFRICA BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 92 SOUTH AFRICA THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 93 SOUTH AFRICA BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)
TABLE 94 SOUTH AFRICA BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 95 SOUTH AFRICA TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 96 SOUTH AFRICA ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)
TABLE 97 SOUTH AFRICA UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 98 SOUTH AFRICA LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 99 SOUTH AFRICA ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 100 SOUTH AFRICA GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 101 SOUTH AFRICA GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 102 SOUTH AFRICA NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 103 SOUTH AFRICA NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 104 SOUTH AFRICA TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 105 SOUTH AFRICA ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 106 SOUTH AFRICA HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 107 SOUTH AFRICA ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 108 SOUTH AFRICA INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 109 UNITED ARAB EMIRATES ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 110 UNITED ARAB EMIRATES MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 111 UNITED ARAB EMIRATES HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 112 UNITED ARAB EMIRATES HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)
TABLE 113 UNITED ARAB EMIRATES BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 114 UNITED ARAB EMIRATES THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 115 UNITED ARAB EMIRATES BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)
TABLE 116 UNITED ARAB EMIRATES BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 117 UNITED ARAB EMIRATES TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 118 UNITED ARAB EMIRATES ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)
TABLE 119 UNITED ARAB EMIRATES UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 120 UNITED ARAB EMIRATES LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 121 UNITED ARAB EMIRATES ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 122 UNITED ARAB EMIRATES GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 123 UNITED ARAB EMIRATES GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 124 UNITED ARAB EMIRATES NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 125 UNITED ARAB EMIRATES NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 126 UNITED ARAB EMIRATES TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 127 UNITED ARAB EMIRATES ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 128 UNITED ARAB EMIRATES HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 129 UNITED ARAB EMIRATES ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 130 UNITED ARAB EMIRATES INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 131 EGYPT ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 132 EGYPT MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 133 EGYPT HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 134 EGYPT HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)
TABLE 135 EGYPT BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 136 EGYPT THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 137 EGYPT BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)
TABLE 138 EGYPT BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 139 EGYPT TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 140 EGYPT ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)
TABLE 141 EGYPT UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 142 EGYPT LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 143 EGYPT ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 144 EGYPT GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 145 EGYPT GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 146 EGYPT NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 147 EGYPT NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 148 EGYPT TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 149 EGYPT ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 150 EGYPT HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 151 EGYPT ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 152 EGYPT INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 153 ISRAEL ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 154 ISRAEL MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 155 ISRAEL HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 156 ISRAEL HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)
TABLE 157 ISRAEL BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 158 ISRAEL THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 159 ISRAEL BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)
TABLE 160 ISRAEL BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 161 ISRAEL TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 162 ISRAEL ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)
TABLE 163 ISRAEL UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 164 ISRAEL LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 165 ISRAEL ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 166 ISRAEL GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 167 ISRAEL GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 168 ISRAEL NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 169 ISRAEL NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 170 ISRAEL TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 171 ISRAEL ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 172 ISRAEL HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 173 ISRAEL ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 174 ISRAEL INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 175 QATAR ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 176 QATAR MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 177 QATAR HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 178 QATAR HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)
TABLE 179 QATAR BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 180 QATAR THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 181 QATAR BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)
TABLE 182 QATAR BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 183 QATAR TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 184 QATAR ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)
TABLE 185 QATAR UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 186 QATAR LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 187 QATAR ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 188 QATAR GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 189 QATAR GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 190 QATAR NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 191 QATAR NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 192 QATAR TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 193 QATAR ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 194 QATAR HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 195 QATAR ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 196 QATAR INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 197 KUWAIT ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 198 KUWAIT MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 199 KUWAIT HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 200 KUWAIT HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)
TABLE 201 KUWAIT BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 202 KUWAIT THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 203 KUWAIT BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)
TABLE 204 KUWAIT BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 205 KUWAIT TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 206 KUWAIT ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)
TABLE 207 KUWAIT UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 208 KUWAIT LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 209 KUWAIT ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 210 KUWAIT GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 211 KUWAIT GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 212 KUWAIT NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 213 KUWAIT NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 214 KUWAIT TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 215 KUWAIT ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 216 KUWAIT HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 217 KUWAIT ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 218 KUWAIT INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 219 OMAN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 220 OMAN MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 221 OMAN HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 222 OMAN HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)
TABLE 223 OMAN BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 224 OMAN THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 225 OMAN BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)
TABLE 226 OMAN BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 227 OMAN TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 228 OMAN ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)
TABLE 229 OMAN UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 230 OMAN LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 231 OMAN ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 232 OMAN GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 233 OMAN GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 234 OMAN NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 235 OMAN NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 236 OMAN TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 237 OMAN ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 238 OMAN HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 239 OMAN ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 240 OMAN INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 241 BAHRAIN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 242 BAHRAIN MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 243 BAHRAIN HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 244 BAHRAIN HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)
TABLE 245 BAHRAIN BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 246 BAHRAIN THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 247 BAHRAIN BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)
TABLE 248 BAHRAIN BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 249 BAHRAIN TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 250 BAHRAIN ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)
TABLE 251 BAHRAIN UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 252 BAHRAIN LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 253 BAHRAIN ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 254 BAHRAIN GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 255 BAHRAIN GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 256 BAHRAIN NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 257 BAHRAIN NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 258 BAHRAIN TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 259 BAHRAIN ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 260 BAHRAIN HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 261 BAHRAIN ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 262 BAHRAIN INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 263 REST OF MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 264 REST OF MIDDLE EAST AND AFRICA MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 265 REST OF MIDDLE EAST AND AFRICA HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 266 REST OF MIDDLE EAST AND AFRICA HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)
TABLE 267 REST OF MIDDLE EAST AND AFRICA BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 268 REST OF MIDDLE EAST AND AFRICA THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 269 REST OF MIDDLE EAST AND AFRICA BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)
TABLE 270 REST OF MIDDLE EAST AND AFRICA BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 271 REST OF MIDDLE EAST AND AFRICA TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 272 REST OF MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)
TABLE 273 REST OF MIDDLE EAST AND AFRICA UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 274 REST OF MIDDLE EAST AND AFRICA LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 275 REST OF MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 276 EST OF MIDDLE EAST AND AFRICA GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 277 REST OF MIDDLE EAST AND AFRICA GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 278 REST OF MIDDLE EAST AND AFRICA NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 279 REST OF MIDDLE EAST AND AFRICA NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 280 REST OF MIDDLE EAST AND AFRICA TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 281 REST OF MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 282 REST OF MIDDLE EAST AND AFRICA HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 283 REST OF MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 284 REST OF MIDDLE EAST AND AFRICA INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)
图片列表
FIGURE 1 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET: COUNTRYWISE MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET: MULTIVARIATE MODELLING
FIGURE 8 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET: MARKET END-USER COVERAGE GRID
FIGURE 11 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET: SEGMENTATION
FIGURE 12 TWO SEGMENTS COMPRISE THE DOMINICAN REPUBLIC ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE
FIGURE 13 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET: EXECUTIVE SUMMARY
FIGURE 14 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET: STRATEGIC DECISIONS
FIGURE 15 RISING PREVALANCE OF ENDOSCOPIC HEMOSTASIS CASES EXPECTED TO DRIVE THE GROWTH OF THE MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET FROM 2026 TO 2033
FIGURE 16 THE TYPE 2 ENDOSCOPIC HEMOSTASIS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET IN 2026 & 2033
FIGURE 17 COMPANY EVALUATION QUADRANT
FIGURE 18 DROC ANALYSIS
FIGURE 19 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2025
FIGURE 20 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET: BY PRODUCT TYPE , CAGR (2025-2032)
FIGURE 21 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET: BY PRODUCT TYPE , CAGR (2025-2032)
FIGURE 22 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET: BY PRODUCT TYPE , LIFELINE CURVE (2025-2032)
FIGURE 23 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE TYPE, 2025
FIGURE 24 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET: BY PROCEDURE , 2026-2033 (USD THOUSAND)
FIGURE 25 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET: BY PROCEDURE , 2026-2033 (USD THOUSAND)
FIGURE 26 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2025
FIGURE 27 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET: BY APPLICATION, 2026-2033 (USD THOUSAND)
FIGURE 28 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET: BY APPLICATION, 2026-2033 (USD THOUSAND)
FIGURE 29 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET: BY APPLICATION, 2026-2033 (USD THOUSAND)
FIGURE 30 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2025
FIGURE 31 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET: BY END USER, 2026-2033 (USD THOUSAND)
FIGURE 32 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET: BY END USER, 2026-2033 (USD THOUSAND)
FIGURE 33 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET: BY END USER, 2026-2033 (USD THOUSAND)
FIGURE 34 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2025
FIGURE 35 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET: BY DISTRIBUTION CHANNEL, 2026-2033 (USD THOUSAND)
FIGURE 36 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET: BY DISTRIBUTION CHANNEL, 2026-2033 (USD THOUSAND)
FIGURE 37 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET: BY DISTRIBUTION CHANNEL, 2026-2033 (USD THOUSAND)
FIGURE 38 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET: SNAPSHOT (2025)
FIGURE 39 MIDDLE EAST AND AFRICA ENDOSCOPIC HEMOSTASIS MARKET: COMPANY SHARE 2025 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
